Ms. Kristina Hachey reports

THERALASE(R) LISTS WARRANTS ON THE TSXV

The TSX Venture Exchange has accepted for listing up to 20,399,050 common share purchase warrants of Theralase Technologies Inc., bearing Cusip No. 88337V142, for trading on the TSX-V. The warrants are expected to commence trading on the TSX-V at the open of markets on June 9, 2026, under the trading symbol TLT.WT.

The warrants were issued pursuant to a brokered private placement of the company that closed on May 20, 2026, in which the company issued:

1. 19,166,667 units at a price of 24 cents per unit;
2. 1,232,383 non-transferrable compensation options to Research Capital Corp., with each compensation option exercisable to acquire one unit at a price of 24 cents per unit until May 20, 2031.

The private placement raised aggregate gross proceeds of $4.6-million and included the full exercise of the overallotment option by the agent.

Each warrant entitles the holder thereof to purchase one common share in the capital of the company at a price of 32 cents per common share until May 20, 2031. The warrants are governed by the terms of a warrant indenture dated May 20, 2026, between the company and TSX Trust Company of Canada, as warrant agent, a copy of which is available under the company's SEDAR+ profile.

About Theralase Technologies Inc.

Theralase is a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria, and viruses.

We seek Safe Harbor.